No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Synthetic binders developer Aptamer Group has signed a licensing agreement with Alphazyme for the use of an Optimer binder in hotstart PCR applications.
Under the deal, Aptamer will grant Alphazyme a nonexclusive licence to use the enzymemodulating Optimer across its hotstart PCR and NGS products and services. Alphazyme will receive worldwide rights, with the agreement including royalties, milestone payments and a supply arrangement under which Aptamer will manufacture the Optimer, providing additional revenue and supplychain assurance.
The two companies originally entered a development agreement in June 2024, with the final Optimer delivered in December. Alphazyme's internal testing showed temperaturesensitive control of exonuclease and polymerase activity, with the Optimer achieving functionality that typically requires two antibodies, offering both performance and cost benefits.
Aptamer added that a second Optimer development programme with Alphazyme has now completed its development phase, with candidate molecules delivered for testing and early results described as positive.
As of 1100 GMT, Aptamer shares were up 4.79% 0.84p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.